• AIDS lymphomas.

• HIV-associated lymphoma in Africa: an autopsy study in Cote d'Ivoire.

• AIDS-related lymphoma in Brazil. Histopathology, immunophenotype, and association with Epstein-Barr virus.

• Effect of HIV infection on the incidence of lymphoma in Africa.

• Primary renal non-Hodgkin's lymphoma with inferior vena cava involvement: report of one case in HIV-infected patient.

• Value of limited necropsy in HIV-positive patients.

• [Penicilliosis infection: differential diagnosis of non-Hodgkin lymphoma in a patient with HIV infection]

• Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection.

1
UI - 1616963
AU - Middleton GW; Lau RK
TI - AIDS lymphomas.
SO - Int J STD AIDS 1992 May-Jun;3(3):173-81

2
UI - 7927898
AU - Lucas SB; Diomande M; Hounnou A; Beaumel A; Giordano C; Kadio A; Peacock
TI - CS; Honde M; De Cock KM HIV-associated lymphoma in Africa: an autopsy study in Cote d'Ivoire.
SO - Int J Cancer 1994 Oct 1;59(1):20-4
AD - Projet RETRO-CI, Abidjan, Cote d'Ivoire.
HIV infection predisposes to the development of non-Hodgkin lymphoma (NHL). The frequency of NHL among HIV-positive adults and children in sub-Saharan Africa is not known. In 1991-1992, a representative autopsy study of HIV infection was performed in Abidjan, Cote d'Ivoire. Of 247 HIV-positive adult (> 14 years) medical patients dying in hospital, 2.8% had NHL, 1.6% with visceral NHL and 1.2% with primary cerebral lymphoma. The estimated crude incidence of NHL among HIV-positive adults in Abidjan was 84/100,000 per year, 10-fold greater than the expected pre-AIDS incidence of NHL but less than the incidence observed among HIV-positive adults in industrialised countries. None of 78 autopsied HIV-positive children (median age = 17 months) had NHL. HIV infection augments the incidence of NHL among adults in Africa, but short survival with advanced HIV disease probably prevents the major increase in HIV-associated NHL seen in industrialised countries. Survival of HIV-positive children in Africa appears too short to permit the significant development of additional NHL; classic Burkitt lymphoma is not an AIDS-associated tumour in Africa.

3
UI - 8607450
AU - Bacchi CE; Bacchi MM; Rabenhorst SH; Soares FA; Fonseca LE Jr; Barbosa
TI - HS; Weiss LM; Gown AM AIDS-related lymphoma in Brazil. Histopathology, immunophenotype, and association with Epstein-Barr virus.
SO - Am J Clin Pathol 1996 Feb;105(2):230-7
AD - Department of Pathology, State University of Sao Paulo-Botucatu, Brazil.
The occurrence of malignant lymphoma is an increasingly important cause of morbidity and mortality in AIDS patients. The incidence of AIDS-related lymphoma in some developing countries such as Brazil is increasing as the survival of HIV infection has improved. Although there is a clear association between several types of immunodeficiency-related lymphomas and Epstein-Barr virus (EBV), the association of EBV infection in AIDS-related lymphoma in Brazil, where the incidence of AIDS is high, is unknown. Formalin-fixed, paraffin-embedded tissue from 24 cases of AIDS-related lymphoma in Brazil were analyzed for morphologic classification, immunophenotype, and EBV association using in situ hybridization studies with an EBV-EBER1 biotinylated probe. Twenty cases of AIDS-related lymphoma were classified as non-Hodgkin's lymphoma and four cases were Hodgkin's disease. Eleven non-Hodgkin's lymphomas were classified as diffuse large cell type, five cases were small non-cleaved cell, Burkitt-type, and four cases were large cell immunoblastic non-Hodgkin's lymphoma. Eighteen cases were of B-cell phenotype; one was a T-cell lymphoma, and one was classified as null. Epstein-Barr virus (EBV) was demonstrated in the majority of tumor cells of 11 of 20 (55%) of the cases non-Hodgkin's lymphomas and in 3 of 4 (75%) cases of Hodgkin's disease. AIDS-related lymphomas in Brazil are usually of large cell/immunoblastic type, but Hodgkin's disease is also seen. Both non-Hodgkin's lymphoma and Hodgkin's disease are often associated with EBV infection. The non-Hodgkin's lymphoma is predominantly of B-cell phenotype.

4
UI - 8756025
AU - Lucas SB; De Cock KM; Peacock C; Diomande M; Kadio A
TI - Effect of HIV infection on the incidence of lymphoma in Africa.
SO - East Afr Med J 1996 May;73(5 Suppl):S29-30
AD - Dept of Histopathology, UCL Medical School, London.

5
UI - 11976627
AU - Busi Rizzi E; Schinina V; Cristofaro M; Bellussi A; Alba L; Bibbolino C
TI - Primary renal non-Hodgkin's lymphoma with inferior vena cava involvement: report of one case in HIV-infected patient.
SO - Radiol Med (Torino) 2002 Mar;103(3):279-82
AD - Department of Radiology, National Institute for Infectious Diseases L. Spallanzani, Rome, Italy.

6
UI - 11314779
AU - Guerra I; Ortiz E; Portu J; Atares B; Aldamiz-Etxebarria M; De Pablos M
TI - Value of limited necropsy in HIV-positive patients.
SO - Pathol Res Pract 2001;197(3):165-8
AD - Department of Anatomic Pathology, Hospital Txagorritxu, Vitoria-Gasteiz, Alava, Spain. iguerra@htxa.osakidetza.net
We performed limited autopsy with histological examination of tissue cores obtained percutaneously using the Tru-Cut needle and the Jamshidi trocar in 150 adult HIV-positive patients. Data were compared retrospectively with the antemortem clinical diagnosis. Eighty-one percent of the patients were male, and 78% were intravenous drug users. Specimens were obtained from the brain, liver, lung, bone marrow, and kidney of most patients. The main findings included liver cirrhosis in 22 cases (associated with HCV infection in 81%), Pneumocystis carinii pneumonia in 21, Cytomegalovirus (CMV) infection in 19, Mycobacterium avium-intracellulaire (MAI) infection in 17, bacterial pneumonia in 14, tuberculosis in 12, and lymphoma in 13 cases. Forty-six (30.6%) patients had at least one clinical diagnosis that was confirmed by autopsy, i.e., there was 40.6% agreement between pre- and postmortem findings. Forty-six (30.6%) patients had at least one clinical diagnosis that was not confirmed at autopsy, whereas 41 (27.3%) had at least one AIDS-related or unrelated disease that was not suspected clinically. The results obtained by limited autopsy are principally comparable to those achieved by full necropsy, with the advantages of decreasing the contagious risk, saving cost and time, including a rapid final diagnosis, and easily obtaining the consent for postmortem examination so that necropsy studies may be performed on a larger number of patients, thus contributing to a better understanding of the spectrum of HIV infection in our environment.

7
UI - 12221581
AU - von Rothenburg T; Schmid G; Schlottmann R
TI - [Penicilliosis infection: differential diagnosis of non-Hodgkin lymphoma in a patient with HIV infection]
SO - Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2002 Sep;174(9):1178-9
AD - Bochum.

8
UI - 12200356
AU - Spina M; Gabarre J; Rossi G; Fasan M; Schiantarelli C; Nigra E; Mena M;
TI - Antinori A; Ammassari A; Talamini R; Vaccher E; di Gennaro G; Tirelli U Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection.
SO - Blood 2002 Sep 15;100(6):1984-8
AD - Division of Medical Oncology A, National Cancer Institute, Via Pedemontana Occidentale 12, 33081 Aviano (PN), Italy.
A phase 2 prospective study was performed to evaluate the feasibility and activity of a short, dose-intensive chemotherapy regimen and radiotherapy (the Stanford V regimen) plus highly active antiretroviral therapy (HAART) and granulocyte colony-stimulating factor (G-CSF) support in patients with Hodgkin disease and HIV infection. Fifty-nine patients were enrolled. Stanford V was well tolerated and 69% of the patients completed treatment with no dose reduction or delayed chemotherapy administration. The most important dose-limiting side effects were bone marrow toxicity and neurotoxicity. Complete remission was achieved by 81% of the patients, and after a median follow-up of 17 months 33 patients (56%) were alive and disease-free. The estimated 3-year overall survival (OS), disease-free survival (DFS), and freedom from progression (FFP) were 51%, 68%, and 60%, respectively. Probability of FFP was significantly (P =.02) higher among patients with an International Prognostic Score (IPS) of 2 or lower than in those with an IPS higher than 2, and the percentages of FFP at 2 years in these groups were 83% and 41%, respectively. Similarly, the probability of OS was significantly (P =.0004) different in the 2 groups, and the percentages of OS at 3 years were 76% and 33%, respectively. Our data confirm that the Stanford V regimen with concomitant HAART is feasible and active in an HIV setting. However, a more intensive approach should be considered in patients with high IPSs.

The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.

About OncoLink  Contact OncoLink  Privacy statement   Disclaimer  Link to OncoLink  Home
For assistance please visit our HELP section
© Trustees of the University of Pennsylvania